






































Pain and Fatigue in Patients With Ankylosing Spondylitis
Treated With Tumor Necrosis Factor Inhibitors
Multinational Real-World Findings
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Background/Objective: Patients with ankylosing spondylitis (AS) ex-
perience symptoms and comorbidities that impact their health-related qual-
ity of life (HRQoL) and ability to work. This real-world, global survey was
conducted among AS patients receiving tumor necrosis factor inhibitors
(TNFis) to evaluate both the frequency and severity of persistent symp-
toms, and the impact of pain and fatigue on HRQoL, employment status,
and work activity.
Methods: Patients with AS and their treating physicians from 13 countries
across 5 continents completed questionnaires capturing demographics, pa-
tient symptoms, current disease status, HRQoL, current therapy, employment
status, and Work Productivity and Activity Impairment.
Results: Seven hundred five patients who had been receiving a TNFi for
3 months or more and completed both Bath Ankylosing Spondylitis Dis-
ease Activity Index (BASDAI) pain and fatigue domains were included
in the analysis; of these, 37.6% reported high BASDAI pain scores and
41.3% high BASDAI fatigue scores. Medical Outcomes Study–Short
Form, 36-item version 2 domain, 5-dimensional EuroQoL Questionnaire,
and 5-dimensional EuroQoL visual analog scale scores were significantly
lower (p < 0.0001), andWork Productivity and Activity Impairment scores
significantly higher (p < 0.0001), in patients with high levels of pain or fa-
tigue than low levels.
Conclusions: Globally, levels of pain and fatigue remained high in AS
patients receiving TNFi treatment, which were significantly associated
with reduced HRQoL and work productivity. Such persistent symptoms
in usual care suggest a substantial unmet need in AS pharmacologic and
nonpharmacologic therapeutic pathways.
Key Words: ankylosing spondylitis, fatigue, pain, quality of life, tumor
necrosis factor inhibitors
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T he prevalence of ankylosing spondylitis (AS) varies greatlyacross the world, reportedly ranging from 6.5/100,000 in
Japan, 100/100,000 in Mexico, 120/100,000 in Taiwan, 130/
100,000 in Spain, 213/100,000 in Canada, to 540/100,000 in
Turkey.1 Ankylosing spondylitis is characterized by inflammatory
back pain and sacroiliac joint structural damagewith or without pe-
ripheral arthritis and fatigue. It can lead to spinal stiffness or immo-
bility from vertebral fusions.2–4 Back pain, stiffness, fatigue,
peripheral arthritis, and comorbidities, such as uveitis, inflamma-
tory bowel disease, psoriasis, and osteoporotic fractures pose a sig-
nificant burden, and AS patients, report impaired health-related
quality of life (HRQoL) and ability to work.3–5
Inflammatory back pain is a common complaint in AS pa-
tients and a component of the clinical criteria for the classification
of AS, prevalent in up to 45% of AS patients.6–9 Fatigue, also
common in AS patients, strongly correlates with pain and can be
as difficult to manage, with a reported global prevalence of 45%
based on a study of 6120 patients with rheumatic diseases from
the Netherlands, Belgium, United Kingdom, United States,
Canada, Germany, France, Spain, Argentina, Mexico, Chile, and
Portugal.10–12 Elevated levels of the proinflammatory cytokines tu-
mor necrosis factor α (TNF-α), interleukin 6 (IL-6), IL-23, and
IL-17 are present in the serum of patients with AS13 and implicated
in mediation of inflammatory pain, fatigue, and depression.14–19
Until recently, TNF inhibitors (TNFis) were the main biologic
disease-modifying antirheumatic drugs for treatment of patients
with persistently high disease activity despite regular use of nonste-
roidal anti-inflammatory drugs (NSAIDs).20
The purpose of this global real-world study in AS patients
was to evaluate the frequency and severity of symptoms despite
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treatment with TNFis and the relationship of pain and fatiguewith
important patient-centric outcomes including HRQoL, employ-
ment status and work activity, and impairment.
METHODS
Data Source
This analysis of data from the Adelphi Spondyloarthritis AS
Disease Specific Programme (DSP) was conducted in 13 coun-
tries between 2015 and 2016 in North America (NAmerica cover-
ing the United States and Mexico), Europe (EU5, covering
France, Germany, Italy, Spain, the United Kingdom), Asia Pacific
(APAC, covering Japan, South Korea, Taiwan, Australia), and
Turkey and Middle East (T&ME, covering Turkey and the
United Arab Emirates).21 DSPs are large, multinational surveys
designed to identify current disease management and patient-
and physician-reported disease impact. They are point-in-time
surveys conducted in real-world clinical practice.
Physicians included in the survey completed a prespecified
form for the next 1 to 8 (variable by country) consecutive patients
with AS seen for diagnosis or routine care. Physician-reported
forms included detailed questions querying patient demographics,
clinical assessments, concomitant conditions (including fibromy-
algia), medication use, and treatment history. Each patient for
whom a form was completed by the physician was invited to com-
plete a voluntary patient-reported form, providing informed con-
sent to participate.
Patient-reported forms included the 3-level 5-dimension
EuroQoL questionnaire (EQ-5D-3L) deriving both the EQ-5D
health utility and avisual analog scale (EQ-VAS), recording general
health status,22 Bath Ankylosing Spondylitis Disease Activity In-
dex (BASDAI),23 Medical Outcomes Study–Short Form (36-
item) Health Survey version 2 (SF-36v2),24 and Work Productivity
and Activity Impairment General Health Questionnaire (WPAI).25
Patients completed forms independently from physicians and re-
turned them in sealed envelopes to ensure confidentiality.
The DSP collected retrospective data using a noninterventional
market research approach; no identifiable protected health information
was collected. The DSPwas conducted in accordancewith the rel-
evant legislation at time of data collection including the USHealth
Insurance Portability and Accountability Act 199626 and Health
Information Technology for Economic and Clinical Health Act
legislation.27 As this market research was run in accordance with
the European Pharmaceutical Marketing Research Association
guidelines, it did not require ethics committee approvals.28
Participating Physicians and Patients
Rheumatologists (and orthopedists and internists in Japan)
were eligible to participate in the DSP if they had worked for
3 years or more as a physician, had qualified between 1979 and
2012, and were responsible for treatment decisions and manage-
ment of AS patients.
Patients were eligible for inclusion in the AS DSP if 18 years
or older with a physician-confirmed diagnosis of AS and not cur-
rently involved in a clinical trial. There were no exclusion criteria
for the DSP. Patients were included in the analysis if receiving
TNFis for 3 months or more and had completed both BASDAI
pain and fatigue domains. Of 1508 eligible patients, 705 patients
completed the BASDAI pain and fatigue domains and could be in-
cluded in the analysis. However, demographic characteristics of
1508 eligible patients have been similar to the final 705 patients
included in the analysis.
Study Variables
The BASDAI pain scores from BASDAI question 2 (overall
level of neck, back, or hip pain in past 7 days) were stratified into
low pain (<5) and high pain (5–10) to define patient groups.23
Fatigue, assessed using the first question of BASDAI, has
been validated as an effective measure.29 The fatigue scale as-
sesses levels of fatigue by asking “How would you describe the
overall level of fatigue/tiredness you have experienced in the last
week?” scored on a 10-point scale from 1 “none” to 10 “worst.”
Fatigue was arbitrarily divided into low scores (<5) and high
scores (5–10).
FIGURE 1. Pain and fatigue levels by region. Pain and fatigue were assessed by splitting the BASDAI pain and fatigue data into a low (score <5)
and high (score 5–10). N America, the United States andMexico; APAC, Asia Pacific Region; EU5, Europe; T&ME, Turkey and the Middle East.
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Patient characteristics were provided by physicians and in-
cluded demographics, comorbidities, disease status including du-
ration of disease, disease activity (judged by the physician and
measured by physician-reported BASDAI if available), presence
of inflammation indicated by elevated erythrocyte sedimentation
rate (ESR), and/or C-reactive protein (CRP), and treatment details
including type of TNFi therapy and use of prescribed and
nonprescribed pain medications. The BASDAI pain domains,
EQ-5D-3L, SF-36v2 domains, employment status, andWPAI also
assessed patient outcomes.25,30 The SF-36v2 age and sex normative
data were generated based on US norms published in SF-36 man-
uals and updates.31 Patient-reported happiness was assessed using
SF-36v2 question 9, “How much of the time during the past week
have you been happy?”with possible responses: all of the time, most
of the time, some of the time, a little of the time, and none of the time.
Statistical Analyses
Categorical variables were described by counts and propor-
tion of respondents, and continuous numerical variables were de-
scribed by their means and standard deviations. Descriptive
analyses were conducted at a global level and regional levels (N
America, EU5, APAC, T&ME).
At a global level, pain and fatigue cohorts were compared
against each other to assess whether high pain or high fatigue was
associated with differences in other study measures. Statistical
differences by levels of pain and fatigue were assessed using
Kruskal-Wallis tests for continuous or ordinal data and χ2 tests for
categorical data. A significance level of 95% was used throughout.
All analyses used Stata Statistical Software: Release 15
(StataCorp LP, College Station, TX).
RESULTS
Patients and Physicians
Data from a total of 2887 AS patients were collected in the
DSP. One thousand five hundred eight patients (52.2%) had been
receiving a TNFi for 3 months or more at the time of data collec-
tion, of whom 705 (46.8%), who had completed both BASDAI
pain and fatigue domains, were included in this analysis (N
America, n = 253; EU5, n = 328; APAC, n = 88; T&ME,
n = 36). The demographics of included patients across regions
were as follows: males from 75.5% in North America to 100%
in T&ME, mean age in years from 36.1 in T&ME to 45.1 in
EU5, mean years of disease duration from 1.3 in T&ME to 8.4
in EU5, patients who had ever received only 1 TNFi from
83.8% in N America to 97.2% in T&ME, physician-reported dis-
ease severity as “mild” from 60.5% in N America to 86.1% in
T&ME, and physician-reported comorbid fibromyalgia from
2.7% in EU5 to 8.0% in APAC (Supplementary Table 1, http://
links.lww.com/RHU/A207). The included patients were treated
by a total of 307 physicians from 13 countries (N America,
n = 85; EU5, n = 145; APAC, n = 52; T&ME, n = 25).
Of 705 patients included in the analysis, 705 patients (100%)
completed SF-36v2, 694 patients (98.4%) completed EQ-5D-3L,
and 685 patients (97.2%) completed WPAI questionnaires, with
525 patients (74.5%) employed at the time of questionnaire
completion.
Levels of Pain and Fatigue
Stratification of patients based on pain levels resulted in 2
groups: one with low BASDAI pain scores: less than 5, n = 440
(62.4%); and the other with high BASDAI pain: 5 to 10,
n = 265 (37.6%). Stratification of patients based on fatigue levels
resulted in 2 groups: lowBASDAI fatigue scores: less than 5, n = 414
(58.7%); and the other with high BASDAI fatigue: 5 to 10, n = 291
(41.2%). Rates of high pain and fatigue were similar for N America,
EU5 and APAC regions, but not for T&ME. Although T&ME pa-
tients reported the greatest levels of high pain and fatigue (86.1%
and 88.9%, respectively), this must be interpreted with caution due
to the small sample size (n = 36) (Fig. 1).
The BASDAI pain and fatigue domains used to stratify these
cohorts were highly correlated with both the pain dimension of
EQ-5D-3L and the SF-36v2 vitality (VT) domains (BASDAI pain
and EQ-5D-3L pain, Spearman correlation coefficient = 0.5391;
BASDAI fatigue and SF-36v2 VT, Spearman correlation coeffi-
cient = 0.6099). The BASDAI pain domain was also highly corre-
lated with the BASDAI fatigue domain (Spearman correlation
coefficient = 0.8400).
Patient Demographics and Clinical Characteristics
by Pain and Fatigue Levels
Patient characteristics including body mass index, time since
symptom onset and diagnosis, and human leukocyte antigen B27
status were similar between patients with low or high pain and/or
fatigue. Patients who reported high pain levels tended to be
slightly older compared with those with low levels (45.8 vs.
42.2 years). Comorbid fibromyalgia was reported in 7.9% and
7.6% of patients with high levels of pain and fatigue, respectively,
and 2.3% and 2.2% in patients with low pain and fatigue levels,
respectively (Table 1).
Significant differences in disease severity and disease status
were observed in patients reporting high pain (both p < 0.0001)
and/or fatigue (p < 0.0001 and p = 0.0005, respectively) than in
those reporting low pain and/or fatigue. A higher proportion of pa-
tients with high pain and/or fatigue were reported to have disease
rated as “severe” (from mild/moderate/severe) by their physician
than those with low pain and/or fatigue (high vs. low pain; 9.1%
vs. 2.3%; high vs. low fatigue: 8.2% vs. 2.4%) (Table 2). A higher
proportion of patients with high pain and/or fatigue levels were re-
ported to have physician-rated disease status as “unstable” or “de-
teriorating” than those with low pain and/or fatigue levels (high
vs. low pain: 14.4% vs. 2.5%; high vs. low fatigue: 14.1% vs.
1.9%). Significant differences were observed in current flare sta-
tus between patients reporting high pain and/or fatigue (both
p < 0.0001). Current flares were more frequently reported in pa-
tients with high rather than low pain levels (11.4% vs. 3.2%), as
well as those with high versus low fatigue levels (11% vs.
2.9%). However, a notable proportion of patients with high pain
(39.6%) and/or fatigue (40.2%) were deemed to be in remission,
whereas 85.6% and 85.9% of patients with high levels of pain
and/or fatigue, respectively, were considered to have stable or im-
proving disease by their treating physician, indicating discordance
between patient-reported and physicians' assessment of disease.
Patients with high pain and/or fatigue levels had significantly
higher levels of the inflammatory markers CRP and ESR than
those with low pain and/or fatigue levels. C-reactive protein levels
in patients reporting high versus low pain were 6.3 versus
4.3 mg/L, respectively (p = 0.0006), and 5.8 versus 4.5 mg/L, re-
spectively (p = 0.0243), in patients reporting high versus low fa-
tigue. Erythrocyte sedimentation rate levels in patients reporting
high versus low pain were 18.3 versus 14.1 mm/h, respectively
(p = 0.003), and 18.2 versus 13.9 mm/h, respectively (p = 0.0005),
in patients reporting high versus low fatigue.
HRQoL by Pain and Fatigue Levels
The SF-36v2 scores were compared between patients
reporting low or high pain and fatigue levels and against
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age- and sex-matched normative data (Fig. 2). Patients with
low pain and fatigue reported scores that approximated norms
across most SF-36v2 domains; however, among patients with
high pain and fatigue, scores across all SF-36v2 domains were
significantly lower versus patients with low pain and fatigue
(both p < 0.0001).















(n = 291) p value
Current severity,a n (%)
Mild 460 (65.2) 346 (78.6) 114 (43.0) <0.0001 324 (78.3) 136 (46.7) <0.0001
Moderate 211 (29.9) 84 (19.1) 127 (47.9) 80 (19.3) 131 (45.0)
Severe 34 (4.8) 10 (2.3) 24 (9.1) 10 (2.4) 24 (8.2)
In remission, n (%) 382 (54.2) 277 (63.0) 105 (39.6) <0.0001 265 (64.0) 117 (40.2) <0.0001
Disease status, n (%) (n = 704) (n = 440) (n = 264) <0.0001 (n = 414) (n = 290)
Stable/improving 655 (93.0) 429 (97.5) 226 (85.6) 406 (98.1) 249 (85.9) 0.0005
Unstable/deteriorating 49 (7.0) 11 (2.5) 38 (14.4) 8 (2.0) 41 (14.1)
Current flare status, n (%) (n = 704) (n = 440) (n = 264) <0.0001 (n = 414) (n = 290) <0.0001
Never flared 389 (55.3) 280 (63.6) 109 (41.3) 256 (61.8) 133 (45.9)
Flares, not current 271 (38.5) 146 (33.2) 125 (47.3) 146 (35.3) 125 (43.1)
Current flares 44 (6.3) 14 (3.2) 30 (11.4) 12 (2.9) 32 (11.0)
ESR, mm/h (n = 409) (n = 252) (n = 157) (n = 238) (n = 171)
Mean (SD) 15.7 (13.1) 14.1 (12.3) 18.3 (13.9) 0.0003 13.9 (12.1) 18.2 (13.9) 0.0005
CRP, mg/L (n = 386) (n = 242) (n = 144) (n = 224) (n = 162)
Mean (SD) 5.0 (7.6) 4.3 (6.2) 6.3 (9.3) 0.0006 4.5 (6.4) 5.8 (8.9) 0.0243
BASDAI score (n = 253) (n = 157) (n = 96) (n = 150) (n = 103)
Mean (SD) 3.0 (2.2) 2.7 (2.2) 3.6 (2.1) <0.0001 2.8 (2.2) 3.4 (2.1) 0.0041
aPhysician-reported.

















Male, n (%) 549 (77.9) 349 (79.3) 200 (75.5) 331 (80.0) 218 (74.9)
BMI, mean (SD), kg/m2 25.7 (3.8) 25.5 (3.7) 26.0 (3.9) 25.4 (3.6) 26.0 (4.0)
Age, y
Mean (SD) 43.6 (12.2) 42.2 (12.0) 45.8 (12.4) 42.1 (12.0) 45.7 (12.2)
<65 y, n (%) 666 (94.5) 424 (96.4) 242 (91.3) 399 (96.4) 267 (91.8)
Symptom duration, y (n = 623) (n = 390) (n = 233) (n = 367) (n = 256)
Mean (SD) 10.5 (9.4) 10.4 (9.0) 10.8 (10.1) 10.9 (9.0) 10.0 (9.9)
Disease diagnosis duration, y (n = 648) (n = 410) (n = 238) (n = 381) (n = 267)
Mean (SD) 7.3 (7.8) 7.1 (6.9) 7.8 (9.2) 7.4 (7.1) 7.2 (8.8)
HLA-B27 status, n (%) (n = 487) (n = 324) (n = 163) (n = 313) (n = 174)
+ ve, n (%) 434 (89.1) 290 (89.5) 144 (88.3) 282 (90.1) 152 (87.4)
Peripheral joint involvement, n (%) 335 (47.5) 193 (43.9) 142 (53.6) 184 (44.4) 151 (51.9)
Comorbid fibromyalgia, n (%) 31 (4.4) 10 (2.3) 21 (7.9) 9 (2.2) 22 (7.6)
No. TNFis ever received, n (%)
1 610 (86.5) 384 (87.3) 226 (85.3) 366 (88.4) 244 (83.8)
2 63 (8.9) 40 (9.1) 23 (8.7) 35 (8.5) 28 (9.6)
≥3 16 (2.3) 9 (2.0) 7 (2.6) 6 (1.4) 10 (3.4)
Unknown 16 (2.3) 7 (1.6) 9 (3.4) 7 (1.7) 9 (3.1)
The bold entries indicates the n values differ from the overall n value provided in the column header.
BMI, body mass index; HLA-B27, human leukocyte antigen B27.
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More patients reporting high pain and/or fatigue reported
less happiness in the past week by SF-36v2 compared with low
pain and/or fatigue; 29.5% of patients with high pain and 30.3%
with high fatigue reported feeling happy a “little or none of the
time” versus 12.0% of patients with low pain and 10.3% of pa-
tients with low fatigue (p < 0.0001) (Table 3).
Regional SF-36v2 mean domain scores can be found in Sup-
plementary Table 2, http://links.lww.com/RHU/A207. Patients from
T&ME had lower scores across all domains compared with other re-
gions. Physical functioning domainmean scores ranged from 32.8 in
T&ME to 71.4 in EU5. This wide range in scores between T&ME
and other regions was observed for all domains with the exception
of the General Health Questionnaire and VT domains, in which
mean scores ranged from 44.9 in T&ME to 55.0 in N America
and from 48.8 in T&ME to 57.4 in N America and APAC.
A significantly higher percentage of patients reporting high
pain or fatigue reported “some” or “extreme” problems with mo-
bility, self-care, usual activities, pain, and anxiety/depression as
measured by EQ-5D-3L compared with those reporting low pain
and fatigue (p < 0.0001) (Fig. 3). Regional EQ-5D-3L health
utility and EQ-VAS scores (Table 3) were significantly lower in
patients reporting high pain and/or fatigue levels compared with
low pain and/or fatigue (all p < 0.0001).
Regional mean EQ-5D-3L and EQ-VAS scores can be found
in Supplementary Table 2, http://links.lww.com/RHU/A207. The
EQ-5D-3L scores were similar between N America, EU5, and
APAC ranging from 0.773 in EU5 to 0.808 in APAC; however,
the T&ME EQ-5D-3L score was low at 0.149. The EQ-VAS
scores ranged from 56.7 in T&ME to 77.4 in N America.
All nonreference BASDAI domains were significantly
higher in patients with high pain and/or fatigue levels. Patients
with high pain and/or fatigue levels also reported significantly
higher BASDAI scores for joint pain and swelling (other than
neck, back, or hip), discomfort, and severity and duration of morn-
ing stiffness (p < 0.0001) compared with patients reporting low
pain and/or fatigue (Table 3). Regional mean BASDAI scores
can be found in Supplementary Table 2, http://links.lww.com/
RHU/A207. Regional mean scores for N America, EU5, and
APAC across all BASDAI domains ranged from 2.6 in APAC
(for “pain, swelling in other joints”) to 3.9 in EU5 (for “fatigue/
FIGURE 2. Spydergram of SF-36v2 domain scores by pain (A) and fatigue (B) levels. A/G, age/sex. All p < 0.0001.
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tiredness level”). Mean BASDAI scores for T&ME were greater
than 6.0 for all domains apart from morning stiffness duration,
which had a score of 4.6.
Societal Burden by Pain and Fatigue Levels
Of 631 patients who provided employment information and
were of working age (<65 years), 525 (83.2%) were employed, de-
fined as employed, a student, or a homemaker (Table 4). Employ-
ment status differed significantly: patients reporting high pain
(n = 164, 71.6%) had lower employment status compared with
those reporting low pain (n = 361, 89.8%; p < 0.0001), and there
was higher retirement or unemployment due to AS in patients
reporting high pain (n = 25, 10.9%) compared with low pain
(n = 30, 7.5%; p < 0.0001). Similar results were evident with fa-
tigue: there were lower employment rates in patients reporting
high fatigue (n = 188, 74.3%) compared with low fatigue
(n = 337, 89.2%; p < 0.0001) and higher retirement or unemploy-
ment due to AS in patients reporting high fatigue (n = 29, 11.5%)
compared with low fatigue (n = 26, 6.9%; p < 0.0001).
The mean percentage (SD) of overall work impairment
among all included patients was 27.6% (25.7%). All WPAI mea-
sures were significantly higher in patients with high pain and/or fa-
tigue levels compared with low pain and/or fatigue (p < 0.0001),
indicating that high pain and/or fatigue are associated with more
work impairment, work time missed, impairment while working,
and impairment in daily activities (Table 4).
Societal burden by region is shown in Supplementary Table 2,
http://links.lww.com/RHU/A207. More than 80% of patients in all
regionswere employed. Overall work impairment and presenteeism
were less than 25% inNAmerica, EU5, andAPAC, but greater than
60% in T&ME. Absenteeism was also highest in T&ME at 16.4%
compared with 2.7%, 4.9%, and 6.9% in APAC, N America, and
EU5, respectively.
Use of Pain Medication by Pain Levels
Globally, more than twice the number of patients reporting
high pain levels reported using nonprescription pain medications
than those with low pain (27.9% vs. 10.8%; p < 0.0001). Prescrip-
tion pain medications included NSAIDs (including cyclooxygen-
ase 2 inhibitors), nonopioids, and opioids. Significantly more
patients reporting high pain levels received NSAIDs compared
with patients reporting low pain levels (52.8% vs. 39.3%;
p = 0.0006). Use of nonopioid prescription medications was sim-
ilar in patients reporting high and low pain levels (Fig. 4).
DISCUSSION
The present analysis of real-world patient- and physician-reported
data is the first global study examining the association between pain
and/or fatigue with HRQoL andWPAI in AS patients treated with
TNFis.We have demonstrated that increasing severity of pain and/
or fatigue are associated with impaired HRQoL and mental well-
ness, as well as reduced physical functioning, engagement in ac-
tivities, and work productivity.
Managing pain is an important treatment goal in patients
with AS, however, pain is often underestimated by clinical disease
activity scoring tools, and 20% to 30% of patients report pain de-
spite treatment with TNFis.6,32,33 We observed increased levels of
inflammatory markers with increasing severity of pain, indicating
that patients may not have been adequately responding to therapy
or were poorly adherent with their TNFis. The former concept is
supported by previous work demonstrating that switching TNFi
is often delayed in patients with AS despite lack of efficacy.12,34
Inflammatory mediators in AS can directly and indirectly influ-
ence pain, with animal studies demonstrating that IL-17 can con-
tribute to neuroinflammatory responses and pain hypersensitivity
following neuropathic injury.14 However, pain in AS is not only
inflammatory, but also may involve soft tissue causes associated
with muscle deconditioning, as well as a neuropathic component;











BASDAI, mean (SD)a (n = 702) (n = 439) (n = 263) (n = 413) (n = 289)
Fatigue/tiredness level (reference) 3.9 (2.7) 2.4 (1.8) 6.5 (1.7) 1.9 (1.2) 6.8 (1.3)
Neck, back or hip pain (reference) 3.7 (2.7) 1.9 (1.3) 6.7 (1.3) 2.0 (1.6) 6.1 (2.0)
Pain, swelling in other joints 3.0 (2.7) 1.5 (1.5) 5.4 (2.4) 1.5 (1.4) 5.2 (2.5)
Discomfortb 3.2 (2.7) 1.7 (1.5) 5.7 (2.3) 1.6 (1.4) 5.4 (2.4)
Morning stiffness severity 3.4 (2.6) 2.0 (1.5) 5.8 (2.2) 1.9 (1.4) 5.6 (2.3)
Morning stiffness duration 3.2 (2.5) 2.0 (1.7) 5.0 (2.6) 2.0 (1.7) 4.8 (2.6)
EQ-5D-3L (n = 694) (n = 434) (n = 260) (n = 408) (n = 286)
Mean (SD) 0.755 (0.279) 0.877 (0.149) 0.550 (0.321) 0.889 (0.134) 0.563 (0.317)
EQ-VAS (n = 704) (n = 440) (n = 264) (n = 414) (n = 290)
Mean (SD) 70.2 (21.5) 78.3 (18.5) 56.7 (19.4) 78.2 (19.1) 58.6 (19.5)
SF-36v2 Q9; happy, n (%) (n = 699) (n = 435) (n = 264) (n = 409) (n = 290)
All of the time/most of the time 336 (48.1) 265 (60.9) 71 (26.9) 261 (63.8) 75 (25.9)
Some of the time 233 (33.3) 118 (27.1) 115 (43.6) 106 (25.9) 127 (43.8)
A little of the time/none of the time 130 (18.6) 52 (12.0) 78 (29.5) 42 (10.3) 88 (30.3)
All p < 0.0001.
aBase varies by domain, minimum base shown.
bOverall discomfort from areas tender to touch or pressure.
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therefore, strategies to treat chronic pain might differ from those
that target inflammation.35
We observed a strong correlation between pain and fatigue
levels, consistent with a UK study where fatigue was most
strongly associated with pain in patients with AS compared with
all other factors explored including age, depression, motivation,
anxiety, physical activity, and sleep.12 The pathology of fatigue
is unknown; however, the high prevalence of fatigue in rheumatic
diseases and significantly increased levels of inflammatory
markers observed in AS patients with severe fatigue suggest that
inflammation is a likely contributing factor.10 This is consistent
with several studies establishing that elevated levels of proinflam-
matory cytokines are associated with debilitating fatigue in auto-
immune and inflammatory disorders.36 This also suggests that
patients with high levels of proinflammatory cytokines may have
persistent inflammatory disease.37,38
Consistent with a Scottish registry study,6 our global study
demonstrates that pain and/or fatigue are common complaints in
AS patients treated with TNFi and are associated with reduced
HRQoL and that fatigue is not reliably controlled by pain manage-
ment. Severe fatigue is described as overwhelming, unlike normal
tiredness, permeating every aspect of life and difficult to
self-manage with little outside support,39 and inadequate relief
of both pain and/or fatigue have been shown to contribute to re-
duced HRQoL.40,41
We also observed discordance between patient-reported
symptoms and physicians' assessments of disease in our global
sample of AS patients, where some patients reporting high levels
of pain and/or fatigue were deemed to be in remission or have sta-
ble or improving disease by their physician. Patient-physician dis-
cordance is well documented in rheumatology, and our data agree
with other studies demonstrating discordance between patient and
physician perceptions of AS, highlighting the importance of ap-
propriate evaluation and management of pain and fatigue in the
management of AS.42–45
We observed that globally, work impairment including ab-
senteeism and presenteeism affected 27.6% of AS patients, con-
sistent with previous studies.46 Our study also demonstrated that











Current employment status among patients of working age, n (%) (n = 631) (n = 402) (n = 229) (n = 378) (n = 253)
Employed/student/homemaker 525 (83.2) 361 (89.8) 164 (71.6) 337 (89.2) 188 (74.3)
Unemployed/retired due to condition 51 (8.1) 11 (2.7) 40 (17.5) 15 (4.0) 36 (14.2)
Unemployed/retired not due to condition or unspecified 55 (8.7) 30 (7.5) 25 (10.9) 26 (6.9) 29 (11.5)
WPAI: % overall work impairment (n = 415) (n = 280) (n = 135) (n = 259) (n = 156)
Mean (SD) 27.6 (25.7) 15.9 (15.7) 51.7 (25.5) 14.7 (14.5) 48.9 (25.9)
WPAI: % presenteeism (n = 427) (n = 289) (n = 138) (n = 268) (n = 159)
Mean (SD) 24.8 (23.9) 13.6 (13.1) 48.3 (24.3) 12.6 (12.2) 45.3 (24.7)
WPAI: % absenteeism (n = 422) (n = 283) (n = 139) (n = 262) (n = 160)
Mean (SD) 6.4 (15.0) 3.7 (11.9) 11.9 (18.9) 3.2 (11.5) 11.5 (18.4)
WPAI: % activity Impairment (n = 685) (n = 428) (n = 257) (n = 406) (n = 279)
Mean (SD) 32.2 (26.6) 17.7 (15.5) 56.2 (23.7) 16.5 (14.5) 54.9 (23.6)
All p < 0.0001.
FIGURE 3. The 3-level 5-dimension EuroQoL questionnaire by pain and fatigue levels. Categories of EQ-5D-3L response are percentage of
patients with (A) no problems, (B) some problems, (C) confined to bed/unable to perform task/extreme problem; (B) and (C) are shown on
graph. p values across (A–C) response categories of EQ-5D-3L for each level of pain and fatigue are all p < 0.0001.
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patients with severe pain and/or fatigue report an impaired ability
to work and high rates of unemployment and retirement. This is
consistent with reports that impaired work productivity is associ-
ated with fatigue in patients with axial spondyloarthritis,46 and
overall employment rates are significantly lower in AS patients
than in the general population.47 An impaired ability to work im-
pacts HRQoL and is costly to society as a whole.48,49 In the
NOR-DMARD study, the cost of absenteeism in AS patients tak-
ing biologic disease-modifying antirheumatic drugs over a 2-year
period was €115,319.49
A major strength of this study is that it presents real-world
data in AS patients treated with TNFi around the world and the
negative impact of pain and/or fatigue on HRQoL and WPAI.
Real-world studies play an important part in highlighting areas
of concern that are not addressed in clinical trials. Patients in-
cluded in clinical trials represent a small proportion of the consult-
ing population as a result of age restrictions and stringent
eligibility criteria, which typically exclude many comorbidities.50
Patients treated in the real-world setting may be less likely to be
adherent to medication than those included in clinical trials.51
As a result, data from real-world studies can complement clinical
trials and provide insight into the efficacy of interventions in pa-
tients commonly seen in clinical practice. Although the DSPs
are exploratory studies that complement rather than replace larger
studies, advantages include the ability to rapidly perform studies
in relatively small populations that nonetheless provide insights
into diseases, attitudes, and outcomes that might otherwise be dif-
ficult to obtain in such a timely manner and at in-depth patient
level. A consistent methodology is used for DSPs across countries
and economic environments, enabling cross-country compari-
sons, in comparison with registries or databases specific for a par-
ticular country or region. DSPs can include elements related to
patient-reported outcomes and impacts on usual activities, provid-
ing insights into aspects not routinely assessed in randomized clin-
ical trials. DSPs can be used to complement data from clinical
trials performed in well-defined but potentially unrepresentative
populations to provide an update on data otherwise obtained from
large-scale but costly and time-consuming epidemiological stud-
ies. A recent DSP validity article has been published.52
Several potential limitations associated with data derived
from this cross-sectional, real-world study should be considered.
Cross-sectional studies are limited in their selection of patients,
sample sizes, and data collection. A primary limitation of this
studywas that working agewas set to those younger than 65 years;
however, working age varies by country. The diagnosis of AS was
based primarily on the judgment and diagnostic skills of the re-
spondent physician, and a formalized diagnostic checklist was
not mandated. However, this is consistent with the diagnostic de-
cisions made by physicians in routine clinical practice and there-
fore reflects real-world practice. In contrast to a clinical trial
where disease activity is assessed by validated measures,
physician's rating of disease activity, including remission status,
in our study may be considered subjective and hence represents
a limitation. The sample collected was not a random sample of
AS patients as the DSP methodology states that the next “n” con-
sulting patients meeting the inclusion criteria are included. There-
fore, they were not fully representative of the overall population of
AS patients as patients who consult frequently were more likely to
be included in the sample. The DSP systematic approach to re-
cruitment nevertheless reduces selection bias. Although physi-
cians are requested to collect data on a series of consecutive
patients to avoid selection bias, in the absence of randomization
this is contingent on the integrity of the participating physician
rather than formalized source verification procedures. Addition-
ally, because of the cross-sectional nature of our study, levels of
pain and/or fatigue were captured only at the time of data collec-
tion. Therefore, a change in levels of pain and/or fatigue while
on TNFi treatment could not be assessed, and there were no data
collected on levels of pain and/or fatigue before starting such ther-
apy. Limited evidence exists to determine appropriate cutoff points
for pain and fatigue, somidpoints of 5 were used to allow consistent
proportions and comparisons across all countries included in the
study. Also, data for our study were obtained in 2015–2016; there-
fore, limited data were available for biologic treatments other than
TNFis. We observed that overall physician-reported comorbid fi-
bromyalgia levels were low but increased in the patient groups with
high pain and/or fatigue; however, we are aware that variability in
reporting fibromyalgia regionally may be due to different levels of
sensitivity and instruments used, and we cannot determine the im-
pact of undiagnosed fibromyalgia on our results. Another limitation
is that although Ankylosing Spondylitis Disease Activity Score is a
key measure for disease activity in AS, there was low utilization of
Ankylosing Spondylitis Disease Activity Score in our study. How-
ever, our study reflects how physicians practice in a real-world clin-
ical setting where assessments may be more holistic rather than
focusing solely on disease activity. Finally, although recall bias is
a common limitation of surveys, data were collected at the time of
patients' appointments, reducing the likelihood of recall bias.
FIGURE 4. Use of pain medication by pain levels. OTC, over the counter.
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CONCLUSIONS
This real-world study agrees with previous reports that AS
patients commonly report pain despite apparent control of disease
with commonly available biologic therapies such as TNFis.35
These persistent high pain and/or fatigue levels place a high bur-
den on patients in terms of HRQoL, reducing their ability to con-
tribute to society as part of the workforce. Improved treatment
options (in addition to TNFis) in AS are urgently needed, and ap-
propriate evaluation and management of pain and/or fatigue
should be a focus of outcome measures in AS clinical trials. Our
observations indicate the importance of appropriately treating
AS to minimize the impact on patients' social lives, work partici-
pation, and economic and health burdens. Lastly, our results high-
light the need to explore other therapeutic approaches including
nonpharmacologic interventions for the management of AS.
KEY POINTS
• This is the first global study examining the association between
pain and/or fatigue with HRQoL and work productivity in AS
patients treated with TNFis.
• We have demonstrated that increasing severity of pain and/or fa-
tigue are associated with impaired HRQoL andmental wellness,
as well as reduced physical functioning, engagement in activi-
ties, and work productivity.
• Our conclusions agree with previous reports that AS patients
commonly report pain despite apparent control of disease with
commonly available biologic therapies such as TNFis.
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